Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

atugen AG Discovers Novel Cancer Target

21.01.2003


atugen AG, a private company focused on the elucidation of disease pathways, today announced the identification of a novel cancer target that appears to play an important role in tumor growth and metastasis. atugen’s research group has demonstrated that inhibition of the novel target, Atu027, which has homology to protein kinases, results in blockage of tumor growth of human prostate carcinoma cells in orthotopic mouse models. atugen has demonstrated that human prostate tumor cells engineered to express siRNA molecules against the kinase shows significant reduction or even complete lack of secondary tumors indicating a role of the kinase in tumor progression and metastasis.



The novel target, Atu027, is the result of the company’s internal research program on the phosphatidylinositol 3-OH kinase (PI 3-K) pathway. The approach was presented at the Cold Spring Harbor Laboratory’s Tumor Suppressor August 2002 Meeting in Cold Spring Harbor, NY. PI 3-K is a central signal transduction molecule controlling a wide range of cellular responses including contributing to increased malignant behavior of cancer cells.

The identification and functional validation of the kinase as PI 3-K downstream effector molecule underscores the strength of the atugen approach to find novel targets. The use of the company’s proprietary mRNA knockdown technologies (GeneBlocs® antisense molecules, improved synthetic siRNA, vector expression systems for siRNA, ribozymes and superior transfection reagents) together with atugen’s expertise in gene function elucidation has to date resulted in 19 functionally validated cancer targets that act in the PI 3-K pathway.


“We are in the process of out-licensing this novel kinase target to partners,” said Dr. Klaus Giese, atugen’s Chief Scientific Officer and Vice President of Research. “The breakthrough in this complex pathway endorses our approach, which aims at providing our partners and in-house projects with the best targets for therapeutic intervention within a given disease cascade. We have already started to dissect a complementary pathway, the TGF-beta/Smad pathway.”

Caroline Stupnicka | alfa
Further information:
http://www.atugen.de

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>